Browsing Tag
fruquintinib
5 posts
HUTCHMED’s ATTC platform and fruquintinib combo data headline 2025 R&D updates
Find out how HUTCHMED’s new ATTC platform and strong late-stage trial results could reshape its cancer drug pipeline and investor outlook today.
Quebec lists Takeda’s FRUZAQLA for metastatic colorectal cancer under RAMQ formulary
Quebec approves public reimbursement of Takeda’s FRUZAQLA for metastatic colorectal cancer, expanding treatment access in Canada.
China NMPA accepts NDA for Innovent and HUTCHMED’s sintilimab-fruquintinib combo in advanced renal cell carcinoma
Innovent Biologics (HKEX: 01801) and HUTCHMED (NASDAQ: HCM) secure NDA acceptance in China for sintilimab-fruquintinib in RCC, signaling oncology market shift.
Takeda’s FRUZAQLA gains Health Canada approval, offering hope for metastatic colorectal cancer patients
Takeda Canada Inc. has achieved a significant milestone with the Health Canada approval of FRUZAQLA (fruquintinib), a targeted…
Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary…